Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.

ABSTRACT:

Purpose

Age has long been used as a major factor for assessing suitability for allogeneic hematopoietic cell transplantation (HCT). The HCT-comorbidity index (HCT-CI) was developed as a measure of health status to predict mortality risk after HCT. Whether age, comorbidities, or both should guide decision making for HCT is unknown.

Patients and methods

Data from 3,033 consecutive recipients of HLA-matched grafts from five institutions contributed to this analysis. Patients were randomly divided into a training set to develop weights for age intervals and a validation set to assess the performance of prognostic models.

Results

In the training set, patients age 20 to 39 years, 40 to 49 years, 50 to 59 years, and ≥ 60 years had hazard ratios for nonrelapse mortality (NRM)

SUBMITTER: Sorror ML 

PROVIDER: S-EPMC4178523 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature